AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

RENERGEN LTD-CDI

0.750

0.000

Volume:- -

Turnover:- -

Market Cap:116.38M

PE:-6.36

High:0.750

Open:0.750

Low:0.750

Close:0.750

52wk High:1.495

52wk Low:0.685

Shares:155.17M

Float Shares:119.78M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.118

EPS(LYR):-0.118

ROE:-28.37%

ROA:-6.76%

PB:1.79

PE(LYR):-6.36

Loading ...

Overview Company News Filings

ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives

ASX Midday Sector Update: Energy Stocks Climb, Real Estate Struggles

MT Newswires Live

Renergen Securities Suspended From Quotation

MT Newswires Live

Renergen, ASP Isotopes' Scheme of Arrangement Now Unconditional

MT Newswires Live

ProstACT Global Phase 3 Update: First Patient Dosed in Randomized Treatment Expansion, Part 1 Readout Plans Confirmed

Renergen, ASP Isotopes Extends Deadline to Meet Acquisition Conditions

MT Newswires Live

Renergen Sees Wider Loss Per Share for Six Months Ended Aug. 31; Shares Rise 11%

MT Newswires Live

Renergen Shares Fall After It Says Key Conditions for Merger with ASP Isotopes Achieved

MT Newswires Live

LabConnect Partners with The Bracken Group to Expand Radiopharmaceutical Support Services

Shares of Renergen Rise After Reaching Settlement With Springbok Solar

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/stock/RLT.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RLT.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RLT.AU\",,,,,undefined,":{"symbol":"RLT.AU","market":"AU","secType":"STK","nameCN":"RENERGEN LTD-CDI","latestPrice":0.75,"timestamp":1787551200000,"preClose":0.75,"halted":0,"volume":0,"delay":0,"changeRate":0,"nameEN":"RENERGEN LTD-CDI","floatShares":119781496,"shares":155170900,"eps":-0.11793642600146603,"marketStatus":"Not Yet Opened","change":0,"latestTime":"08-24 16:00:00 AEST","open":0.75,"high":0.75,"low":0.75,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.11793642600146603,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1787616000000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.75,"openAndCloseTimeList":[[1787529600000,1787551200000]],"volumeRatio":0,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"RLT.AU","preClose":0.815,"auctionPrice":0.75,"auctionVolume":1368,"auction":3,"marketStatus":"盘后竞价","timestamp":1767071398087}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RLT.AU\",,,,,undefined,":{"symbol":"RLT.AU","floatShares":119781496,"roa":"-6.76%","roe":"-28.37%","lyrEps":-0.117935,"shares":155170900,"dividePrice":0,"high":0.75,"amplitude":0,"preClose":0.75,"low":0.75,"week52Low":0.685,"pbRate":"1.79","psRate":"28.24","week52High":1.495,"institutionHeld":0,"latestPrice":0.75,"eps":-0.11793642600146603,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.11793642600146603,"open":0.75,"prevYearClose":0.75,"prevWeekClose":0.75,"prevMonthClose":0.75,"prevQuarterClose":0.75,"fiveDayClose":0.75,"twentyDayClose":0.75,"sixtyDayClose":0.75},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RLT.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2026-01-13","symbol":"RLT.AU","reason":null,"defaultRemindTime":1768258800000,"announcedDate":"2026-01-12","type":"delisting","dateTimestamp":1768222800000},{"market":"AU","date":"2025-09-08","symbol":"RLT.AU","reason":null,"defaultRemindTime":1757289600000,"announcedDate":"2025-06-13","type":"delisting","dateTimestamp":1757253600000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RLT.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RLT.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2618366608","title":"ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives","url":"https://stock-news.laohu8.com/highlight/detail?id=2618366608","media":"prnewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618366608?lang=en_us&edition=fundamental","pubTime":"2026-03-10 06:34","pubTimestamp":1773095640,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and INDIANAPOLIS, March 10, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited  today announces that Part 1 of the ProstACT Global Phase 3 study, the safety and dosimetry lead-in for its therapeutic candidate – TLX591-Tx  – has achieved its primary objectives, demonstrating an acceptable safety and tolerability profile with no new safety signals observed.Neeraj Agarwal, MD, Professor of Medicine and Presidential Endowed Chair of Cancer Research at Huntsman Cancer Institute, Salt Lake City, and ProstACT Global Principal Investigator and Steering Committee member, commented, \"These results reinforce the feasibility of integrating TLX591-Tx with current standard of care therapies for mCRPC, including ARPIs such as enzalutamide or abiraterone, or docetaxel. Hematologic events align with those typically seen in this patient population and therapeutic class, and these cases resolved quickly. The dosimetry profile, along with the low-grade nature of non-hematologic advers","market":"sg","thumbnail":"https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/prostact-global-phase-3-study-part-1-achieves-primary-objectives-302708664.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7061","BK4141","TLX","BK4213","BK7067","BK7039","BK4543","BK7095","SOC.AU","IND.AU","BK4526","BK7142","TLX.AU","RLT.AU","ASX.AU","SOC","IND","BK4139","ASX","SEC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2595574617","title":"ASX Midday Sector Update: Energy Stocks Climb, Real Estate Struggles","url":"https://stock-news.laohu8.com/highlight/detail?id=2595574617","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595574617?lang=en_us&edition=fundamental","pubTime":"2025-12-31 08:38","pubTimestamp":1767141538,"startTime":"0","endTime":"0","summary":"Energy stocks advanced 0.6% at midday Wednesday in the year's last trading session on the Australian bourse, with Brent crude prices holding steady.Renergen's  securities were suspended from quotation on Wednesday in accordance with the timetable for its acquisition by Nasdaq-listed ASP Isotopes through a scheme of arrangement.On the flip side, the real estate sector fell 0.6%.The Lederer Group encouraged members of the Elanor Commercial Property Fund  to vote in favor of a resolution to remove Elanor Funds Management as the responsible entity of the fund and appoint Evolution Trustee as the new responsible Lederer is convening a meeting of members of the Elanor Commercial Property Fund to vote on the resolution on Jan. 30, 2026. Lederer confirmed its plans to vote its around 42.68% interest in the fund in favor of the resolution.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ECF.AU","BK7142","BK7122","BK7154","RLT.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2595745667","title":"Renergen Securities Suspended From Quotation","url":"https://stock-news.laohu8.com/highlight/detail?id=2595745667","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595745667?lang=en_us&edition=fundamental","pubTime":"2025-12-31 08:01","pubTimestamp":1767139305,"startTime":"0","endTime":"0","summary":"Renergen's  securities were suspended from quotation on Wednesday, in accordance with the timetable for its acquisition by Nasdaq-listed ASP Isotopes through a scheme of arrangement, according to a same-day filing with the Australian bourse.The compliance certificate was received from the Takeover Panel on Dec. 18, according to a separate filing.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7142","RLT.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2592431946","title":"Renergen, ASP Isotopes' Scheme of Arrangement Now Unconditional","url":"https://stock-news.laohu8.com/highlight/detail?id=2592431946","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592431946?lang=en_us&edition=fundamental","pubTime":"2025-12-18 06:20","pubTimestamp":1766010056,"startTime":"0","endTime":"0","summary":"Renergen  and ASP Isotopes  said the remaining conditions for the company's acquisition by ASPI have been met, and the scheme of arrangement is now unconditional, according to a Thursday filing with the Australian bourse.The company expects the deal to be implemented after the receipt of the Takeover Panel compliance certificate on Thursday, the filing said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7142","ASPI","BK4109","RLT.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2589060328","title":"ProstACT Global Phase 3 Update: First Patient Dosed in Randomized Treatment Expansion, Part 1 Readout Plans Confirmed","url":"https://stock-news.laohu8.com/highlight/detail?id=2589060328","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589060328?lang=en_us&edition=fundamental","pubTime":"2025-12-08 06:08","pubTimestamp":1765145280,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and INDIANAPOLIS, Dec. 8, 2025 /PRNewswire/ --Telix Pharmaceuticals Limited  today announces that the first patienthas been dosed in Part 2  of its ProstACT Global Phase 3 study evaluating its lead prostate cancer therapy candidate TLX591  in patients with metastatic castration resistant prostate cancer . The patient was dosed at the Australian Prostate Centre  in Melbourne, Australia.ProstACT Global is the first Phase 3 trial to combine aPSMA[1]-targeted radio antibody-drug conjugate  therapy administered together with Standard of Care  versus SOC alone. Part 2 of ProstACT Global will enroll approximately 490 patients and is currently recruiting patients in Australia, New Zealand and Canada.As previously agreed with FDA and disclosed to the market, Telix will submit Part 1 data to the United States  Food and Drug Administration  to enable clearance to expand Part 2 of the trial to U.S. sites. A public disclosure of preliminary results from Part 1 of the study will","market":"hk","thumbnail":"https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/prostact-global-phase-3-update-first-patient-dosed-in-randomized-treatment-expansion-part-1-readout-plans-confirmed-302634831.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX","BK7095","LU1066051811.HKD","APC","BK4141","TLX.AU","LU2237443978.SGD","LU0786609619.USD","SEC.AU","ASX","BK4543","LU0882574139.USD","LU2456880835.USD","LU0053666078.USD","LU0314104364.USD","LU1935042991.SGD","LU1066051498.USD","LU2083900584.USD","LU0149725797.USD","BK4526","BK7067","LU1066051225.USD","LU1718418525.SGD","LU1935043536.SGD","LU1935043023.USD","EMA.AU","EMA","LU2237443549.SGD","APC.AU","LU0077335932.USD","LU1496350171.SGD","BK4139","LU2237443382.USD","BK7129","XKO.AU","LU1935042488.USD","CTA","ASX.AU","RLT.AU","BK7142","XAO.AU","XJO.AU","LU1674673691.USD","LU2236285917.USD","LU2420271590.USD","LU2237443622.USD","LU1066053197.SGD","LU0170899867.USD","LU1366192091.USD","LU1778281490.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2586727175","title":"Renergen, ASP Isotopes Extends Deadline to Meet Acquisition Conditions","url":"https://stock-news.laohu8.com/highlight/detail?id=2586727175","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586727175?lang=en_us&edition=fundamental","pubTime":"2025-11-28 09:45","pubTimestamp":1764294333,"startTime":"0","endTime":"0","summary":"Renergen  and ASP Isotopes  have agreed to extend the deadline to meet the remaining conditions for Renergen's acquisition by ASPI to Jan.30, 2026, according to a Friday filing with the Australian bourse.The company's repayment of the funding advanced to it by ASPI has also been extended to the same date, the filing said.Shares of the company fell 1% in recent Friday trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RLT.AU","BK4109","BK7142","ASPI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2579914939","title":"Renergen Sees Wider Loss Per Share for Six Months Ended Aug. 31; Shares Rise 11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579914939","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579914939?lang=en_us&edition=fundamental","pubTime":"2025-10-29 08:13","pubTimestamp":1761696828,"startTime":"0","endTime":"0","summary":"Renergen  said it expects loss per share in the range of 0.866 South African Rand to 0.957 South African Rand, for the six months ended Aug. 31, wider than the actual result of 0.4573 South African Rand last year, according to a Wednesday filing with the Australian bourse.Shares of the company rose past 11% in recent Wednesday trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XJO.AU","XAO.AU","BK7142","XKO.AU","RLT.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2572583256","title":"Renergen Shares Fall After It Says Key Conditions for Merger with ASP Isotopes Achieved","url":"https://stock-news.laohu8.com/highlight/detail?id=2572583256","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572583256?lang=en_us&edition=fundamental","pubTime":"2025-10-01 14:01","pubTimestamp":1759298460,"startTime":"0","endTime":"0","summary":"The shares of Renergen fell over 5% in recent trading on Wednesday after the firm said late on Tuesday that key conditions for the merger between Renergen and ASP Isotopes had been received, and the final regulatory approvals from South Africa were the primary gating item before the merger is completed.The firm and the Springbok solar project executed both a settlement and coexistence agreement, under which both the Virginia gas project and the solar project can operate within the designated area, with clear protocols for ongoing communication and operational coordination.The firm's liquefied natural gas production fell to 987 tons in the quarter compared to 1,311 tons from the previous quarter's production.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7142","RLT.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2569715859","title":"LabConnect Partners with The Bracken Group to Expand Radiopharmaceutical Support Services","url":"https://stock-news.laohu8.com/highlight/detail?id=2569715859","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569715859?lang=en_us&edition=fundamental","pubTime":"2025-09-23 21:15","pubTimestamp":1758633300,"startTime":"0","endTime":"0","summary":"The Bracken Group  is widely recognized for its scientific leadership and strategic expertise in the radiopharma space. Known for key opinion leadership and a broad scientific approach, Bracken brings unmatched insights across development, regulatory, and commercialization efforts.LabConnect's unique combination of state-of-the-art technology, world-class laboratories, easy access to major and emerging markets, and extensive specialized testing expertise means that drug development companies can rely on one provider for all their central laboratory service needs.About BrackenThe Bracken Group offers consulting, regulatory, analytics, marketing, and sales enablement solutions for the life sciences and digital health industries. Through highly experienced consultative support, business programs, and data-enabled products, Bracken provides a multidisciplinary approach to exceeding goals for their clients.","market":"sg","thumbnail":"https://mma.prnewswire.com/media/2611513/LabConnect_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2611513/LabConnect_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/labconnect-partners-with-the-bracken-group-to-expand-radiopharmaceutical-support-services-302564086.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RLT.AU","BK7142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2569176340","title":"Shares of Renergen Rise After Reaching Settlement With Springbok Solar","url":"https://stock-news.laohu8.com/highlight/detail?id=2569176340","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569176340?lang=en_us&edition=fundamental","pubTime":"2025-09-23 11:50","pubTimestamp":1758599453,"startTime":"0","endTime":"0","summary":"Shares of Renergen  rose 9% in recent Tuesday trade after it said in a late Monday filing that it settled all legal disputes with Springbok Solar power plant.Under the agreement, the parties have defined clear protocols and have agreed to allow both the Virginia Gas project and the Springbok Solar project to operate within the designated area, the filing said.The company's unit Tetra4 will keep exclusive rights under a production right in areas outside the agreed boundary of the project, the filing added.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RLT.AU","BK7142"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":10,"code":"91000000","status":"200"}]}}